Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients

Autor: Kristy Ott-Napier, Kathleen Simpson, Michele R. Vaughan, Lori Backus, John M. Racadio, Patrick Warren, Robert Spavin, Devon J. Dishman, Beth Stockman, James I. Geller, Joe Conner, Keri A. Streby, Marianne M Brunner, Alexander J. Towbin, Mark A. Currier, Timothy P. Cripe, Melinda Triplet

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 23(14)

Purpose: HSV1716 is an oncolytic herpes simplex virus-1 (HSV-1) studied in adults via injection into the brain and superficial tumors. To determine the safety of administering HSV1716 to pediatric patients with cancer, we conducted a phase I trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dbdea6ef492420a537b187e746a18e49
https://pubmed.ncbi.nlm.nih.gov/28495911

Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.

Autor: Streby KA; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.; Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital Research Institute, Columbus, Ohio., Geller JI; Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio., Currier MA; Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital Research Institute, Columbus, Ohio., Warren PS; Department of Radiology, Nationwide Children's Hospital, Columbus, Ohio., Racadio JM; Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Towbin AJ; Department of Radiology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Vaughan MR; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio., Triplet M; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio., Ott-Napier K; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio., Dishman DJ; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio., Backus LR; Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio., Stockman B; Division of Oncology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio., Brunner M; Translational Research Trials Office, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio., Simpson K; Virttu Biologics Ltd, Biocity, Scotland, United Kingdom., Spavin R; Virttu Biologics Ltd, Biocity, Scotland, United Kingdom., Conner J; Virttu Biologics Ltd, Biocity, Scotland, United Kingdom., Cripe TP; Division of Hematology/Oncology/BMT, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio. Timothy.Cripe@nationwidechildrens.org.; Center for Childhood Cancer and Blood Diseases, Nationwide Children's Hospital Research Institute, Columbus, Ohio.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Jul 15; Vol. 23 (14), pp. 3566-3574. Date of Electronic Publication: 2017 May 11.